GURU.Markets stock price, segment price, and overall market index valuation
The company's share price TNFA
The value of TNF Pharmaceuticals, like any early-stage biopharmaceutical company, is determined by the potential of its developments. The potential share price will depend on the results of clinical trials and the ability to commercialize its drugs.
Share prices of companies in the market segment - Pharma other
TNF Pharmaceuticals is a biopharmaceutical company focused on developing tumor necrosis factor (TNF)-targeted drugs for the treatment of inflammatory diseases. We classified it in the "Other Pharmaceuticals" category. The chart below shows how the market values companies with highly specialized developments.
Broad Market Index - GURU.Markets
TNF Pharmaceuticals is a pharmaceutical company developing drugs targeting tumor necrosis factor (TNF) for the treatment of inflammatory diseases. Its focus on this niche makes it a prominent player in the GURU.Markets index. The chart below shows the entire market. Find out how TNF Pharma compares to it.
Change in the price of a company, segment, and market as a whole per day
TNFA - Daily change in the company's share price TNFA
For TNF Pharmaceuticals Inc., a pharmaceutical company, daily volatility reflects sensitivity to scientific data. This metric is an important component in formulas that assess the risk and potential of companies in the biotechnology sector.
Daily change in the price of a set of shares in a market segment - Pharma other
TScan Therapeutics (TNFA) develops cutting-edge T-cell therapies to combat cancer, operating in one of the most innovative and volatile segments of biotech. The chart below reflects average daily fluctuations in this industry. It can help you assess whether TNFA's stock price is reflecting internal news or general sentiment in the cell therapy sector.
Daily change in the price of a broad market stock, index - GURU.Markets
TNF Pharmaceuticals is a pharmaceutical company developing new drugs. Its shares, like many in the sector, are volatile and react to news about clinical trials. These scientifically driven movements are part of the overall stock market landscape.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization TNFA
TNF Pharmaceuticals' year-over-year performance is a story of drug development for the treatment of inflammatory and oncological diseases. Its 12-month market capitalization depends entirely on progress in preclinical and early clinical trials, where the company must prove the potential of its scientific platform to create effective and safe drugs.
Annual dynamics of market capitalization of the market segment - Pharma other
As an early-stage biotech company, TNF is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials. Its stock price will reflect investors' speculative belief in the potential of its unique developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
TNF Pharmaceuticals, an early-stage biotech, is likely focused on tumor necrosis factor (TNF) inhibitors. Its market capitalization dynamics are largely uncorrelated with the market and reflect pure scientific risk. Investors are betting that its research will lead to the creation of a new class of anti-inflammatory drugs.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization TNFA
TNF Pharma is a pharmaceutical company. Its monthly performance is typical for the sector: it depends on progress in its scientific developments and clinical programs. News of trial results for its tumor necrosis factor-targeted drugs are the main drivers.
Monthly dynamics of market capitalization of the market segment - Pharma other
TNF Pharmaceuticals is a biopharmaceutical company likely focused on developing drugs targeting tumor necrosis factor (TNF), a key inflammatory mediator. Success depends on clinical data. The pharmaceutical sector's performance will reflect overall interest in immunology, which provides a backdrop for assessing the company's development potential.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
TNF Pharmaceuticals is an early-stage biotech company. Its shares are extremely volatile and completely uncorrelated with the market. Any news about preclinical trials or funding can cause sharp movements. The stock price of such a company reflects speculative expectations, not fundamental trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization TNFA
TNF Pharmaceuticals, like any early-stage biopharmaceutical company, is a high-risk asset. Its weekly stock price performance reflects investors' faith in its scientific approach rather than financial flows. News about preclinical studies or patents can cause sharp fluctuations.
Weekly dynamics of market capitalization of the market segment - Pharma other
TNF Pharmaceuticals is an early-stage biotech company whose research focuses on new approaches to treating inflammatory diseases. Its shares move not with the market, but rather on expectations of scientific breakthroughs. The chart will show how independent its performance is from the pharmaceutical sector average.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
TNF Pharmaceuticals is an early-stage biotech company. Its shares represent a venture-backed bet on science and can exhibit extreme volatility on news releases. The chart clearly demonstrates how its weekly performance can be out of sync with overall market movements.
Market capitalization of the company, segment and market as a whole
TNFA - Market capitalization of the company TNFA
TNF Pharmaceuticals' market capitalization reflects investor sentiment for its developments in inflammatory disease treatments. Its performance will depend entirely on progress in its research targeting tumor necrosis factor (TNF). Its extremely small value reflects the company's very early stage and high speculative interest.
TNFA - Share of the company's market capitalization TNFA within the market segment - Pharma other
TNF Pharmaceuticals is an early-stage biopharmaceutical company. Its market share in the sector is virtually nonexistent, as is typical for such companies. Its market capitalization reflects the value of its intellectual property and the scientific hypothesis surrounding tumor necrosis factor (TNF) as a therapeutic target.
Market capitalization of the market segment - Pharma other
This chart shows the overall value of the entire pharmaceutical sector. For TNF Pharmaceuticals, a small biotech company working on specific drugs, this line represents the scale of the ocean in which it operates. The chart's fluctuations reflect global investor sentiment toward the entire industry, against which the company is trying to prove the value of its developments.
Market capitalization of all companies included in a broad market index - GURU.Markets
TNF Pharmaceuticals is an early-stage biotech company. Its market capitalization is essentially a measure of its intellectual property and investors' belief that its scientific ideas can be developed into drugs.
Book value capitalization of the company, segment and market as a whole
TNFA - Book value capitalization of the company TNFA
TNF Pharmaceuticals is a pharmaceutical company, and its book value is its financial resources for research. This consists of cash that allows the company to pursue its research in oncology and inflammatory diseases. How has this research capital changed? The chart below shows.
TNFA - Share of the company's book capitalization TNFA within the market segment - Pharma other
TNF Pharmaceuticals is a biotech company whose research requires a physical base. The company's balance sheet reflects the value of its laboratories, equipped with equipment for conducting research and development. The chart shows the company's share of the physical R&D infrastructure in this innovative sector.
Market segment balance sheet capitalization - Pharma other
TNF Pharmaceuticals is likely a biotech company. Pharmaceuticals, as the graph shows, are knowledge- and capital-intensive. Its capital is intellectual property and R&D infrastructure for clinical trials.
Book value of all companies included in the broad market index - GURU.Markets
TNF Pharmaceuticals' assets are not factories, but a scientific platform for developing a new class of drugs that selectively block the soluble form of tumor necrosis factor (TNF), which could be a safer approach to treating inflammatory diseases. These assets reflect its scientific potential.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - TNFA
TNF Pharmaceuticals is a biopharmaceutical company. Its market valuation reflects its pipeline and investors' confidence in its ability to bring them to market. This is a classic biotech story, where future potential is valued far more than current assets.
Market to book capitalization ratio in a market segment - Pharma other
TNF Pharmaceuticals is a biotech company developing drugs. Its high market valuation on this chart, despite its modest tangible assets, is a classic example of biotech investors buying into scientific potential and the hope of a future blockbuster.
Market to book capitalization ratio for the market as a whole
TNF Pharmaceuticals is a biotech company whose valuation is likely closely tied to its pipeline and patents. This chart helps us understand market sentiment: how willing investors are to invest in long-term, risky scientific projects in the hopes of a future breakthrough.
Debts of the company, segment and market as a whole
TNFA - Company debts TNFA
TNF Pharmaceuticals, an early-stage biotech company, relies entirely on seed funding to finance its preclinical research. At this stage, debt is unlikely, and all capital is spent on proving the scientific concept. This graph reflects the initial, riskiest phase of a company's life.
Market segment debts - Pharma other
TNF Pharmaceuticals is an early-stage pharmaceutical company. For such companies, the primary goal is to raise capital to conduct preclinical studies and validate their scientific ideas. This chart depicts the financial model of a biotech startup that relies entirely on external funding to advance its projects.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio TNFA
TNF Pharmaceuticals is a biotech company focused on developing new treatments. Like most companies in the research stage, it does not have stable revenue. This chart shows its reliance on debt to fund research, which carries high financial risks until the product is commercialized.
Market segment debt to market segment book capitalization - Pharma other
TNF Pharmaceuticals, as its name suggests, is a biopharmaceutical company likely targeting tumor necrosis factor (TNF), an important target in the treatment of inflammatory diseases. This chart shows its financial structure, typical for a biotech startup, relating its debt to the overall market capitalization of the sector.
Debt to book value of all companies in the market
TNF Pharmaceuticals is an early-stage biotech company, likely focused on tumor necrosis factor (TNF). Fundamental research requires significant investment. How heavily will the company rely on debt along the way? This graph of total debt in the economy provides context for assessing the future financial risks of its business model.
P/E of the company, segment and market as a whole
P/E - TNFA
TNF Pharmaceuticals is a biopharmaceutical company specializing in the development of therapies targeting tumor necrosis factor (TNF). This chart reflects speculative investor interest in its research. The valuation is highly volatile and depends on news about preclinical and clinical developments.
P/E of the market segment - Pharma other
TNF Pharmaceuticals is a biopharmaceutical company whose name reflects its focus on developing drugs targeting tumor necrosis factor (TNF), a key mediator of inflammation. This chart illustrates the average valuation in the pharmaceutical sector, where investors evaluate the potential of new approaches to treating inflammatory diseases.
P/E of the market as a whole
TNF Pharmaceuticals is a biopharmaceutical company likely focused on developing tumor necrosis factor (TNF)-targeted drugs for the treatment of inflammatory diseases. This chart reflects investors' overall risk appetite. It helps understand whether TNFA's valuation reflects speculative interest in its research or general trends in biotech.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company TNFA
TNF Pharmaceuticals is an early-stage biotech company focused on developing drugs targeting tumor necrosis factor (TNF), which plays a key role in inflammatory processes. This chart reflects investors' speculative expectations regarding the future success of their scientific platform in developing new treatments.
%20P%2FE%20TNFA&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-TNFA&v=1772603432724 "Chart of the company's future (projected) P/E TNFA")
Future (projected) P/E of the market segment - Pharma other
TNF Pharmaceuticals is a biotech company developing new drugs. Its valuation depends on progress in research and development. The chart shows speculative profitability forecasts for the sector. It allows for a comparison of how the market views TNF Pharma's scientific prospects compared to other biotech companies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-other&v=1772603432767 "Future (projected) P/E graph of the market segment - Pharma other")
Future (projected) P/E of the market as a whole
TNF Pharmaceuticals is in the early stages of drug development. The value of such companies is almost entirely based on expectations and belief in their scientific hypothesis. This graph of overall market sentiment is critically important, as it determines whether investors are willing to fund fundamental science with very high risk and a long-term perspective.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772603432793 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit TNFA
TNF Pharmaceuticals appears to be an early-stage biotech company, whose name indicates its focus on tumor necrosis factor (TNF) inhibitors used to treat inflammatory diseases. Its financial metrics in this chart likely reflect initial research and development costs.
Profit of companies in the market segment - Pharma other
TNF Pharmaceuticals is likely a biotech company whose research focuses on tumor necrosis factor (TNF), a key protein involved in inflammation. This chart illustrates the overall picture in the pharmaceutical sector, where targeting important molecular targets like TNF has already led to several blockbusters.
Overall market profit
TNF Pharmaceuticals is a biopharmaceutical company whose prospects, as its name suggests, may be linked to the development of drugs targeting tumor necrosis factor (TNF). Its activities are not linked to the economic cycles visible in this chart. The company's value is determined by the potential of its scientific developments and the results of clinical trials.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company TNFA
TNF Pharmaceuticals is apparently an early-stage biotech company focused on developing drugs targeting tumor necrosis factor (TNF). Future profits are purely hypothetical and depend on the success of its scientific hypotheses. This chart reflects highly speculative projections of its potential.
%20profit%20of%20the%20company%20TNFA&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-TNFA&v=1772603432990 "Graph of future (projected) profit of the company TNFA")
Future (predicted) profit of companies in the market segment - Pharma other
TNF Pharmaceuticals is a biopharmaceutical company focused on developing new treatments. The company's success depends on its ability to conduct research and bring effective drugs to market. This chart shows general profitability expectations for the pharmaceutical sector, providing a general framework for evaluating the company's performance.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-other&v=1772603433037 "Graph of future (predicted) profits of companies in a market segment - Pharma other")
Future (predicted) profit of the market as a whole
TNF Pharmaceuticals is an early-stage biopharmaceutical company. Its survival and growth depend entirely on raising research funding. This earnings expectations chart reflects the overall sentiment of investors and their willingness to invest in high-risk but potentially breakthrough scientific projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772603433094 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - TNFA
TNF Pharmaceuticals is an early-stage biopharmaceutical company. Its name suggests a focus on tumor necrosis factor (TNF) inhibitors. Revenue is likely nonexistent at this stage. This chart reflects a purely speculative assessment of its scientific hypotheses and potential for treating inflammatory diseases.
P/S market segment - Pharma other
TNF Pharmaceuticals is likely a biotech company whose research focuses on tumor necrosis factor (TNF), a key protein involved in inflammatory processes. Drugs targeting TNF are used to treat many autoimmune diseases. This chart shows the average revenue estimate for the sector, which helps assess the potential of this research area.
P/S of the market as a whole
TNF Pharmaceuticals is a biotech company in the early stages of research and development. For such companies, this chart, which displays the average market revenue estimate, serves as a reminder that their value is almost entirely based on expectations of future success, and traditional valuation methods are not applicable.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company TNFA
TNF Pharmaceuticals, as its name suggests, is a biopharmaceutical company focused on tumor necrosis factor (TNF) inhibitors, which are used to treat inflammatory diseases. For such a company, valuing future revenue reflects investor confidence. The chart shows market expectations for the success of its drug candidates in this large but competitive market.
%20P%2FS%20TNFA&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-TNFA&v=1772603433308 "The graph of the company's future (projected) P/S TNFA")
Future (projected) P/S of the market segment - Pharma other
TNF Pharmaceuticals is a biotech company focused on developing drugs targeting tumor necrosis factor (TNF). This chart compares the company's estimated future sales with industry expectations. It shows how investors view its research and potential for developing new treatments for inflammatory and autoimmune diseases.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20other&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-other&v=1772603433322 "Future (projected) P/S market segment graph - Pharma other")
Future (projected) P/S of the market as a whole
TNF Pharmaceuticals is a biotech company focused on developing novel therapies related to tumor necrosis factor (TNF). As an early-stage company, its success is entirely dependent on future research. This market expectations chart reflects investor appetite for high-risk, high-potential scientific projects.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772603433438 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales TNFA
This chart reflects the financial activity of TNF Pharmaceuticals, a biopharmaceutical company likely in the early stages of development. There are no commercial revenues from product sales. Cash flows, if any, may be related to seed funding for preclinical studies.
Sales of companies in the market segment - Pharma other
TNF Pharmaceuticals is an early-stage biopharmaceutical company focused on developing tumor necrosis factor (TNF)-related therapies. It currently has no revenue. Its valuation is based on the potential of its research, and future revenue depends on the successful advancement of its developments to the clinic.
Overall market sales
TNF Pharmaceuticals is likely a biotech company, whose name hints at its focus on tumor necrosis factor (TNF), a key target in the treatment of inflammatory diseases. Its success will depend on scientific breakthroughs. This general economics chart is irrelevant for assessing a company whose value is created in the laboratory, not in the consumer market.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company TNFA
TNF Pharmaceuticals is a development-stage biopharmaceutical company likely focused on drugs targeting tumor necrosis factor (TNF), which plays a role in many inflammatory diseases. Future revenue is dependent on the success of clinical trials. The chart reflects analyst expectations for the potential of its therapeutic candidates.
%20sales%20of%20the%20company%20TNFA&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-TNFA&v=1772603433706 "Schedule of future (projected) sales of the company TNFA")
Future (projected) sales of companies in the market segment - Pharma other
TNF Pharmaceuticals is a biotechnology company focused on drug development. This chart shows the sales forecast for the entire biotechnology sector. Is the market expected to grow thanks to new discoveries and drug approvals, or will the industry face pricing pressure? This provides an overview of the company's overall performance.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-other&v=1772603433713 "Schedule of future (projected) sales of companies in the market segment - Pharma other")
Future (projected) sales of the market as a whole
TNF Pharmaceuticals is an early-stage biopharmaceutical company. Its name reflects its focus on tumor necrosis factor (TNF), which plays a role in inflammatory processes. The company's success will depend on scientific progress and research data. This macroeconomic trend chart does not reflect the fundamental drivers of its potential growth.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772603433753 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality TNFA
TNF Pharmaceuticals is an early-stage biotech company focused on developing novel therapies related to tumor necrosis factor (TNF). This chart reflects its financial performance during the research phase. Profitability is a very distant goal, dependent entirely on the success of its scientific platform and its ability to attract funding for further development.
Market segment marginality - Pharma other
TNF Pharmaceuticals is an early-stage biopharmaceutical company. Its financial performance is primarily driven by research and development expenses aimed at developing new therapeutics. For such companies, profitability is a distant goal, dependent on successfully completing multiple stages of scientific and clinical development.
Market marginality as a whole
TNF Pharmaceuticals, as its name suggests, likely focuses on developing drugs targeting tumor necrosis factor (TNF), which plays a key role in inflammatory processes. Its success depends on scientific breakthroughs. This gross profitability chart reflects investors' willingness to fund such highly specialized R&D projects.
Employees in the company, segment and market as a whole
Number of employees in the company TNFA
TNF Pharmaceuticals is a very early-stage biotech company. Its staff likely consists of just a few people—the founders and key researchers. This graph will show the minimum headcount typical for startups still in the fundamental research phase and seeking initial funding for their ideas.
Share of the company's employees TNFA within the market segment - Pharma other
TNF Pharmaceuticals is an early-stage biotech company focused on developing new treatments for inflammatory diseases. Its staff likely consists of a small core group of founding scientists. This graph shows a minimal market share, typical for startups, where the intellectual capital of a single researcher can be worth more than an entire department.
Number of employees in the market segment - Pharma other
TNF Pharmaceuticals is focused on developing therapies that target tumor necrosis factor (TNF), a key protein involved in inflammatory processes. The chart reflects overall activity in the pharmaceutical industry. Targeting TNF has already led to the creation of blockbuster drugs, and the company is exploring new, more effective ways to target this target.
Number of employees in the market as a whole
Information about TNF Pharmaceuticals (TNFA) is limited, which is typical for biotech startups. These companies are at the cutting edge of science and are staffed by researchers. Their growth depends on funding and successful experiments, not on general economic trends, as this chart shows, representing the venture side of the labor market.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company TNFA (TNFA)
TNF Pharmaceuticals is a very early, preclinical-stage biotech company developing a novel drug delivery platform. Their valuation represents a pure "option" for success. This chart shows the speculative market value of their scientific concept, divided by the very small, likely founding, team.
%20of%20the%20company%20TNFA%20(TNFA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-TNFA-TNFA&v=1772603434307 "Chart of market capitalization per employee (in thousands of dollars) of the company TNFA (TNFA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma other
TNF Pharmaceuticals (TNFA) is an early-stage biotech company. For such companies, this metric reflects market expectations. Any market capitalization attributable to a small team of scientists is based solely on investors' faith that their scientific hypothesis will lead to a breakthrough drug.
%20by%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-other&v=1772603434358 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma other")
Market capitalization per employee (in thousands of dollars) for the overall market
TNF Pharmaceuticals is an early-stage biotech company. Its valuation is currently purely speculative. This metric reflects investors' faith in the company's underlying scientific hypothesis. Its market capitalization is driven not by operational performance, but by the hope that a small team of scientists will make a significant medical breakthrough.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772603434372 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company TNFA (TNFA)
TNF Pharmaceuticals is a very early, preclinical-stage biotech company focused on developing new treatments for inflammatory diseases. This chart shows the net loss per employee. It reflects the company's small team of scientists, whose work is 100% venture-funded R&D.
%20Chart%20TNFA%20(TNFA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-TNFA-TNFA&v=1772603434441 "Company Profit Per Employee (in thousands of dollars) Chart TNFA (TNFA)")
Profit per employee (in thousands of dollars) in the market segment - Pharma other
TNF Pharmaceuticals is a biotech company focused on developing new treatments for inflammatory diseases. While productivity per employee may be low in early stages of R&D, it reflects investment in future breakthroughs. This chart allows you to assess the company's current status and potential compared to other players in the immunology field.
%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-other&v=1772603434482 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma other")
Profit per employee (in thousands of dollars) for the market as a whole
TNF Pharmaceuticals is a very early-stage biotech company focused on developing a therapy targeting tumor necrosis factor (TNF). It's pure R&D. This chart, reflecting average market profitability, highlights the chasm between the broader economy and biotech, where all value is derived from the hope of future clinical trial success.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772603434542 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee TNFA (TNFA)
TNF Pharmaceuticals is likely a biotech company focused on TNF (tumor necrosis factor) inhibitors. For such early-stage companies, revenue per employee is negligible. The timeline is important for assessing the future: a successful drug in this field represents a multibillion-dollar market with the potential for massive growth.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-TNFA-TNFA&v=1772603434557 "Sales chart per company employee TNFA (TNFA)")
Sales per employee in the market segment - Pharma other
TNF Pharmaceuticals is an early-stage (preclinical) biotech company developing a therapy targeting tumor necrosis factor (TNF). They have no commercial revenue. This chart, showing the average revenue in the sector, serves as a barometer of TNFA's R&D staff burn rate.
Sales per employee for the market as a whole
TNF Pharmaceuticals is an early-stage (preclinical) biotech company focused on developing new treatments for inflammatory diseases. Currently, the company has no commercial revenue. This chart reflects their status as an R&D startup investing in laboratory research.
Short shares by company, segment and market as a whole
Shares shorted by company TNFA (TNFA)
TNF Pharmaceuticals (TNFA) is a preclinical biotech. This chart shows the volume of short positions. Shorting companies at such an early stage is a bet that their science (likely related to tumor necrosis factor, or TNF) will not pan out, which is the case in the vast majority of cases.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-TNFA-TNFA&v=1772603434658 "Short Shares Chart for the Company TNFA (TNFA)")
Shares shorted by market segment - Pharma other
TNF Pharmaceuticals (TNFA) - (likely private or early stage). Regarding the immunopharmaceutical sector, this chart aggregates short positions within it. It reflects investor skepticism regarding the risks of clinical trials, especially in a competitive field like TNF inhibitors, which already has blockbusters.
Shares shorted by the overall market
TNF Pharmaceuticals (TNFA) is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator TNFA (TNFA)
TNF Pharmaceuticals (TNFA) is a biotech company likely focused on treating inflammatory diseases by targeting TNF (tumor necrosis factor). This indicator measures the strength of speculative moves. It shows when the stock is "overheated" (above 70) based on early data or "oversold" (below 30) due to intense competition in the field.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-TNFA-TNFA&v=1772603434770 "RSI 14 indicator chart for the company's stock TNFA (TNFA)")
RSI 14 Market Segment - Pharma other
TNF Pharmaceuticals is an early-stage biopharmaceutical company developing drugs likely targeting TNF (tumor necrosis factor) for the treatment of inflammatory diseases. This chart shows the overall sentiment in the specialty pharmaceutical sector. It helps us understand whether TNFA's momentum is driven by its unique technology or is a general "wave" across the industry.
RSI 14 for the overall market
TNF Pharmaceuticals (TNFA) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast TNFA (TNFA)
TNF Pharmaceuticals is a preclinical-stage biotech developing novel therapies targeting TNF (Tumor Necrosis Factor), which plays a role in many inflammatory diseases. This chart shows the highly speculative average price target from analysts, based on their confidence in this early R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-TNFA-TNFA&v=1772603434811 "A chart showing analyst consensus forecasts for the expected stock price. TNFA (TNFA)")
The difference between the consensus estimate and the actual stock price TNFA (TNFA)
TNF Pharmaceuticals is an early-stage biotech developing drugs targeting TNF (tumor necrosis factor) for the treatment of inflammatory diseases. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their belief in this R&D approach.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-TNFA-TNFA&v=1772603434838 "A chart showing the difference between the consensus forecast and the actual stock price. TNFA (TNFA)")
Analyst consensus forecast for stock prices by market segment - Pharma other
TNF Pharmaceuticals (TNFA) is a biotech company, likely in its early stages, developing drugs targeting TNF (tumor necrosis factor) for the treatment of inflammation. This chart shows analysts' overall expectations for the pharmaceutical sector, reflecting whether experts believe new R&D breakthroughs are possible.
Analysts' consensus forecast for the overall market share price
TNF Pharmaceuticals is an early-stage biotech company focused on developing drugs targeting tumor necrosis factor (TNF). This chart reflects the overall market "risk appetite." For TNF, a high-risk company whose value is based on future expectations, overall market optimism (risk appetite) is critical for raising capital.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index TNFA
TNF Pharmaceuticals is likely an early-stage biotech R&D company focused on TNF (Tumor Necrosis Factor), a key inflammatory trigger in the body. They're betting on a new approach to treating autoimmune diseases. This chart is a pure indicator of faith in their R&D. It doesn't reflect revenue, but rather a speculative valuation of their (very risky) pipeline.
AKIMA Market Segment Index - Pharma other
TNF Pharmaceuticals (TNFA) is a biopharmaceutical company targeting TNF (tumor necrosis factor), a key protein that causes inflammation in autoimmune diseases such as rheumatoid arthritis. This chart shows the segment's average index, helping investors assess how this early-stage company compares to the average risk in the pharmaceutical industry.
The AKIM Index for the overall market
TNF Pharmaceuticals (formerly MyMD) is a company developing immunotherapies for the treatment of age-related and autoimmune diseases (TNF-alpha inhibitors). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this scientific story compares to overall economic trends.
